What is MDClone?
MDClone operates at the vanguard of the health-tech industry, providing a sophisticated platform that empowers healthcare organizations to unlock the value of their data. The company specializes in the creation of synthetic data, which allows researchers and clinicians to conduct complex analyses and discovery processes without compromising patient privacy. This capability is essential for modern healthcare systems that must balance the need for data-driven innovation with stringent regulatory compliance. By fostering a collaborative environment for clinical research, MDClone enables institutions to accelerate their digital transformation, improve patient outcomes, and optimize operational workflows through high-fidelity, privacy-compliant data sets.
How much funding has MDClone raised?
MDClone has raised a total of $99M across 3 funding rounds:
Series A
$10M
Series B
$26M
Series C
$63M
Series A (2018): $10M with participation from Lightspeed Venture Partners and OrbiMed
Series B (2019): $26M, investors not publicly disclosed
Series C (2022): $63M supported by Viola Growth and Warburg Pincus
Key Investors in MDClone
OrbiMed
OrbiMed is a specialized investment firm focused on the healthcare sector, managing capital across biopharmaceuticals, medical devices, and digital health platforms with deep expertise in life sciences.
Lightspeed Venture Partners
Lightspeed Venture Partners is a global multistage venture capital firm that invests in early and growth-stage technology companies across sectors such as enterprise software and infrastructure.
Viola Growth
Viola Growth is an Israeli-based technology growth capital fund that specializes in investing in global companies at the expansion phase, offering financial and operational expertise.
What's next for MDClone?
With the infusion of capital from its latest financing round, MDClone is well-positioned to scale its enterprise-level operations and expand its footprint in the global healthcare market. The company is expected to prioritize the enhancement of its synthetic data engine, focusing on deeper integration with existing electronic health record systems and expanding its suite of analytical tools. As the demand for privacy-preserving data solutions grows, MDClone's strategic roadmap likely includes further international expansion and the development of new partnerships with academic medical centers and pharmaceutical firms. The firm's ability to maintain its technological edge while navigating the complexities of global healthcare regulations will be the primary driver of its long-term market leadership.
See full MDClone company page
